GowdakLHW. Atherosclerosis, Inflammation, and Genetics – And you Thought it Was Just LDL-cholesterol. Arq. Bras. Cardiol. 2020;114(2):273-4.
Gowdak,Luis Henrique Wolff. Atherosclerosis, Inflammation, and Genetics – And you Thought it Was Just LDL-cholesterol. Arq. Bras. Cardiol., v. 114, n. 2, p. 273-274, Feb. 2020.
Gowdak,L.H.W. (2020). Atherosclerosis, Inflammation, and Genetics – And you Thought it Was Just LDL-cholesterol. Arq. Bras. Cardiol.,114(2), 273-274.
Gowdak,Luis Henrique Wolff. Atherosclerosis, Inflammation, and Genetics – And you Thought it Was Just LDL-cholesterol. Arq. Bras. Cardiol. [online]. 2020, vol. 114, n. 2, [cited 2025-09-07], pp.273-274. Available from: <https://abccardiol.org/en/short-editorial/atherosclerosis-inflammation-and-genetics-and-you-thought-it-was-just-ldl-cholesterol/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.
